Related Experiment Video
Updated: Aug 2, 2026

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease
B P Kennedy1, M G Ziegler, M Alford
1Department of Medicine, University of California, San Diego Medical Center, San Diego, CA 92103, USA. bpkennedy@ucsd.edu
Abstract:
Both monoamine oxidase (MAO) A and MAO B in the brain have been implicated in the etiology of Alzheimer's disease. MAO B is elevated in plaque-associated glia in Alzheimer brain. Elevations in MAO A in Alzheimer neurons have been linked to increases in neurotoxic metabolites and neuron loss. We investigated the relationship between cognitive function in Alzheimer patients and post-mortem prefrontal cortex MAO A and B activities. Prefrontal cortex tissue from 92 Alzheimer patients and 74 neurologically normal subjects was obtained at autopsy and analyzed for activities of MAO A and B by radioenzymatic methods. Mini Mental Status Exam was performed on Alzheimer patients within 1 year of death. Alzheimer brains were analyzed for Braak stage, tangles, plaques and choline acetyltransferase activity. Prefrontal cortex MAO B activity was significantly increased by 16% in Alzheimer patients versus normals, whereas MAO A activity was significantly decreased by 17% in these same patients. Neither MAO A nor MAO B activities correlated with cognitive function (MMSE score), choline acetyltransferase activity, plaques, neurofibrillary tangles, Braak stage, or age of disease onset in the Alzheimer patients. With increasing Alzheimer duration or increasing Braak stage, MMSE scores and choline acetyltransferase activity declined, but levels of MAO A and B in prefrontal cortex were unchanged. Patients in the upper quintile for MAO A or B activity did not differ significantly from those in the lowest quintile with respect to MMSE scores or age of Alzheimer disease onset. We conclude that the changes in MAO A and B in the prefrontal cortex occur very early in Alzheimer's disease and remain relatively constant as the disease progresses.
Insights
Monoamine oxidase (MAO) A and B enzyme activities in Alzheimer's disease brains show early changes. MAO B increased while MAO A decreased, remaining constant as the disease progresses.
Area of Science:
- Neuroscience
- Biochemistry
- Neuropathology
Background:
- Monoamine oxidase (MAO) A and B enzymes are implicated in Alzheimer's disease (AD) pathogenesis.
- Elevated MAO B is found in plaque-associated glia, while increased MAO A is linked to neurotoxic metabolites and neuron loss in AD.
Purpose of the Study:
- To investigate the relationship between cognitive function in Alzheimer's patients and post-mortem prefrontal cortex MAO A and B activities.
- To determine if MAO A and B levels correlate with AD neuropathological markers and disease progression.
Main Methods:
- Post-mortem prefrontal cortex tissue from 92 Alzheimer's patients and 74 controls was analyzed for MAO A and B activities using radioenzymatic methods.
- Cognitive function was assessed using the Mini Mental Status Exam (MMSE).
- Brain tissue was analyzed for Braak stage, plaques, tangles, and choline acetyltransferase activity.
Main Results:
- MAO B activity was significantly increased (16%) and MAO A activity significantly decreased (17%) in Alzheimer's patients compared to controls.
- Neither MAO A nor MAO B activities correlated with MMSE scores, choline acetyltransferase activity, plaques, tangles, Braak stage, or age of onset.
- MAO A and B levels remained unchanged as Alzheimer's disease duration or Braak stage increased.
Conclusions:
- Changes in MAO A and B activities in the prefrontal cortex occur early in Alzheimer's disease.
- These enzyme activity changes appear to be stable throughout the disease progression.
- The observed alterations in MAO A and B do not correlate with cognitive decline or neuropathological severity in Alzheimer's patients.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction

